{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:19:09Z","timestamp":1793837949065,"version":"4.6.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005046","name":"Natural Science Foundation of Heilongjiang Province","doi-asserted-by":"publisher","award":["LH2019H069"],"award-info":[{"award-number":["LH2019H069"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2019M661299"],"award-info":[{"award-number":["2019M661299"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young and Middle-aged Innovative Scientific Research Fund of the Second Affiliated Hospital of Harbin Medical University","award":["KYCX2018-05"],"award-info":[{"award-number":["KYCX2018-05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-024-03625-6","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T14:29:06Z","timestamp":1735396146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prognostic value and immune infiltration of a tumor microenvironment-related PTPN6 in metastatic melanoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Rongyao","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonghao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luping","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"3625_CR1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejca.2022.03.008","volume":"170","author":"C Garbe","year":"2022","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. Eur J Cancer. 2022;170:236\u201355.","journal-title":"Eur J Cancer"},{"issue":"10400","key":"3625_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","volume":"402","author":"GV Long","year":"2023","unstructured":"Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023;402(10400):485\u2013502.","journal-title":"Lancet"},{"key":"3625_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","volume":"170","author":"C Garbe","year":"2022","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - update 2022. Eur J Cancer. 2022;170:256\u201384.","journal-title":"Eur J Cancer"},{"issue":"11","key":"3625_CR4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","volume":"20","author":"LE Davis","year":"2019","unstructured":"Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20(11):1366\u201379.","journal-title":"Cancer Biol Ther"},{"issue":"23","key":"3625_CR5","doi-asserted-by":"publisher","first-page":"8984","DOI":"10.3390\/ijms21238984","volume":"21","author":"K Eddy","year":"2020","unstructured":"Eddy K, Chen S. Overcoming Immune Evasion in Melanoma. Int J Mol Sci. 2020;21(23):8984.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"3625_CR6","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.3390\/cancers12102870","volume":"12","author":"I Falcone","year":"2020","unstructured":"Falcone I, Conciatori F, Bazzichetto C, Ferretti G, Cognetti F, Ciuffreda L, et al. Tumor Microenvironment: implications in Melanoma Resistance to targeted therapy and immunotherapy. Cancers (Basel). 2020;12(10):2870.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"3625_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41568-022-00442-9","volume":"22","author":"S Kalaora","year":"2022","unstructured":"Kalaora S, Nagler A, Wargo JA, Samuels Y. Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer. 2022;22(4):195\u2013207.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"3625_CR8","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482\u201392.","journal-title":"Ann Oncol"},{"issue":"3","key":"3625_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"key":"3625_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ctrv.2018.02.004","volume":"65","author":"C Belli","year":"2018","unstructured":"Belli C, Trapani D, Viale G, D\u2019Amico P, Duso BA, Della Vigna P, et al. Targeting the microenvironment in solid tumors. Cancer Treat Rev. 2018;65:22\u201332.","journal-title":"Cancer Treat Rev"},{"key":"3625_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","volume":"387","author":"T Wu","year":"2017","unstructured":"Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61\u20138.","journal-title":"Cancer Lett"},{"issue":"5","key":"3625_CR12","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.3892\/or.2016.4660","volume":"35","author":"Y Yuan","year":"2016","unstructured":"Yuan Y, Jiang YC, Sun CK, Chen QM. Role of the tumor microenvironment in tumor progression and the clinical applications (review). Oncol Rep. 2016;35(5):2499\u2013515.","journal-title":"Oncol Rep"},{"key":"3625_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.phrs.2017.07.006","volume":"123","author":"B Pulluri","year":"2017","unstructured":"Pulluri B, Kumar A, Shaheen M, Jeter J, Sundararajan S. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance. Pharmacol Res. 2017;123:95\u2013102.","journal-title":"Pharmacol Res"},{"key":"3625_CR14","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"issue":"4","key":"3625_CR15","doi-asserted-by":"publisher","first-page":"592","DOI":"10.18632\/aging.101415","volume":"10","author":"D Jia","year":"2018","unstructured":"Jia D, Li S, Li D, Xue H, Yang D, Liu Y. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Aging. 2018;10(4):592\u2013605.","journal-title":"Aging"},{"key":"3625_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3389\/fonc.2020.00333","volume":"10","author":"B Li","year":"2020","unstructured":"Li B, Geng R, Wu Q, Yang Q, Sun S, Zhu S, et al. Alterations in Immune-related genes as potential marker of prognosis in breast Cancer. Front Oncol. 2020;10:333.","journal-title":"Front Oncol"},{"issue":"17","key":"3625_CR17","doi-asserted-by":"publisher","first-page":"6999","DOI":"10.18632\/aging.102233","volume":"11","author":"WH Xu","year":"2019","unstructured":"Xu WH, Xu Y, Wang J, Wan FN, Wang HK, Cao DL, et al. Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment. Aging. 2019;11(17):6999\u20137020.","journal-title":"Aging"},{"issue":"3","key":"3625_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/bjc.2017.208","volume":"117","author":"MH Alonso","year":"2017","unstructured":"Alonso MH, Auss\u00f3 S, Lopez-Doriga A, Cordero D, Guin\u00f3 E, Sol\u00e9 X, et al. Comprehensive analysis of copy number aberrations in microsatellite stable colon cancer in view of stromal component. Br J Cancer. 2017;117(3):421\u201331.","journal-title":"Br J Cancer"},{"key":"3625_CR19","doi-asserted-by":"publisher","first-page":"1024931","DOI":"10.3389\/fimmu.2022.1024931","volume":"13","author":"F Wang","year":"2022","unstructured":"Wang F, Zheng A, Zhang D, Zou T, Xiao M, Chen J, et al. Molecular profiling of core immune-escape genes highlights LCK as an immune-related prognostic biomarker in melanoma. Front Immunol. 2022;13:1024931.","journal-title":"Front Immunol"},{"issue":"48","key":"3625_CR20","doi-asserted-by":"publisher","first-page":"20429","DOI":"10.1073\/pnas.0905139106","volume":"106","author":"D Bogunovic","year":"2009","unstructured":"Bogunovic D, O\u2019Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A. 2009;106(48):20429\u201334.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"3625_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/genes11040435","volume":"11","author":"X Wang","year":"2020","unstructured":"Wang X, Chai Z, Li Y, Long F, Hao Y, Pan G, et al. Identification of potential biomarkers for Anti-PD-1 therapy in melanoma by Weighted Correlation Network Analysis. Genes (Basel). 2020;11(4):435.","journal-title":"Genes (Basel)"},{"key":"3625_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.canlet.2017.01.029","volume":"391","author":"RL Pearlman","year":"2017","unstructured":"Pearlman RL, Montes de Oca MK, Pal HC, Afaq F. Potential therapeutic targets of epithelial-mesenchymal transition in melanoma. Cancer Lett. 2017;391:125\u201340.","journal-title":"Cancer Lett"},{"issue":"8","key":"3625_CR23","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1182\/blood-2006-04-017434","volume":"108","author":"Y Han","year":"2006","unstructured":"Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R. Loss of SHP1 enhances JAK3\/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK\u2009+\u2009anaplastic large-cell lymphoma. Blood. 2006;108(8):2796\u2013803.","journal-title":"Blood"},{"issue":"9B","key":"3625_CR24","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1111\/j.1582-4934.2009.00661.x","volume":"13","author":"H Xiong","year":"2009","unstructured":"Xiong H, Chen ZF, Liang QC, Du W, Chen HM, Su WY, et al. Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2\/STAT3\/STAT5 signalling. J Cell Mol Med. 2009;13(9B):3668\u201379.","journal-title":"J Cell Mol Med"},{"issue":"6","key":"3625_CR25","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s40257-023-00795-3","volume":"24","author":"J Huang","year":"2023","unstructured":"Huang J, Chan SC, Ko S, Lok V, Zhang L, Lin X, et al. Global incidence, mortality, risk factors and trends of Melanoma: a systematic analysis of registries. Am J Clin Dermatol. 2023;24(6):965\u201375.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"3625_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jid.2020.03.943","volume":"141","author":"RW Jenkins","year":"2021","unstructured":"Jenkins RW, Fisher DE. Treatment of Advanced Melanoma in 2020 and Beyond. J Invest Dermatol. 2021;141(1):23\u201331.","journal-title":"J Invest Dermatol"},{"key":"3625_CR27","doi-asserted-by":"publisher","first-page":"654749","DOI":"10.3389\/fimmu.2021.654749","volume":"12","author":"L Huang","year":"2021","unstructured":"Huang L, Xu Y, Fang J, Liu W, Chen J, Liu Z, et al. Targeting STAT3 abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma. Front Immunol. 2021;12:654749.","journal-title":"Front Immunol"},{"key":"3625_CR28","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3390\/ijms24021601","volume":"24","author":"SM Hossain","year":"2023","unstructured":"Hossain SM, Eccles MR. Phenotype switching and the Melanoma Microenvironment; impact on Immunotherapy and Drug Resistance. Int J Mol Sci. 2023;24:1601.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"3625_CR29","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1182\/blood-2005-06-2421","volume":"107","author":"JF Honorat","year":"2006","unstructured":"Honorat JF, Ragab A, Lamant L, Delsol G, Ragab-Thomas J. SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling. Blood. 2006;107(10):4130\u20138.","journal-title":"Blood"},{"issue":"41","key":"3625_CR30","doi-asserted-by":"publisher","first-page":"5252","DOI":"10.1038\/onc.2014.445","volume":"34","author":"LC Fan","year":"2015","unstructured":"Fan LC, Shiau CW, Tai WT, Hung MH, Chu PY, Hsieh FS, et al. SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma. Oncogene. 2015;34(41):5252\u201363.","journal-title":"Oncogene"},{"issue":"11","key":"3625_CR31","first-page":"1251","volume":"22","author":"ZZ Chong","year":"2007","unstructured":"Chong ZZ, Maiese K. The src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol. 2007;22(11):1251\u201367.","journal-title":"Histol Histopathol"},{"issue":"5","key":"3625_CR32","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/ni.1604","volume":"9","author":"H An","year":"2008","unstructured":"An H, Hou J, Zhou J, Zhao W, Xu H, Zheng Y, et al. Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat Immunol. 2008;9(5):542\u201350.","journal-title":"Nat Immunol"},{"issue":"4","key":"3625_CR33","first-page":"3273","volume":"19","author":"L Liu","year":"2019","unstructured":"Liu L, Zhang S, Liu X, Liu J. Aberrant promoter 2 methylation\u2013mediated downregulation of protein tyrosine phosphatase, non\u2013receptor type 6, is associated with progression of esophageal squamous cell carcinoma. Mol Med Rep. 2019;19(4):3273\u201382.","journal-title":"Mol Med Rep"},{"issue":"5","key":"3625_CR34","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.3892\/or.2014.3098","volume":"31","author":"Y Li","year":"2014","unstructured":"Li Y, Yang L, Pan Y, Yang J, Shang Y, Luo J. Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia. Oncol Rep. 2014;31(5):2438\u201346.","journal-title":"Oncol Rep"},{"issue":"9","key":"3625_CR35","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1158\/1078-0432.CCR-16-0934","volume":"23","author":"LR Bollu","year":"2017","unstructured":"Bollu LR, Mazumdar A, Savage MI, Brown PH. Molecular pathways: targeting protein tyrosine phosphatases in Cancer. Clin Cancer Res. 2017;23(9):2136\u201342.","journal-title":"Clin Cancer Res"},{"key":"3625_CR36","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1038\/s41467-020-18298-8","volume":"11","author":"DH Peng","year":"2020","unstructured":"Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, et al. Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8(+) T cell exhaustion. Nat Commun. 2020;11:4520.","journal-title":"Nat Commun"},{"issue":"4","key":"3625_CR37","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"3625_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2017.06.001","volume":"45","author":"J Huynh","year":"2017","unstructured":"Huynh J, Etemadi N, Hollande F, Ernst M, Buchert M. The JAK\/STAT3 axis: a comprehensive drug target for solid malignancies. Semin Cancer Biol. 2017;45:13\u201322.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"3625_CR39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","volume":"19","author":"S Zou","year":"2020","unstructured":"Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X. Targeting STAT3 in Cancer Immunotherapy. Mol Cancer. 2020;19(1):145.","journal-title":"Mol Cancer"},{"issue":"12","key":"3625_CR40","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/nm1325","volume":"11","author":"M Kortylewski","year":"2005","unstructured":"Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11(12):1314\u201321.","journal-title":"Nat Med"},{"key":"3625_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.canlet.2017.12.003","volume":"415","author":"Y Wang","year":"2018","unstructured":"Wang Y, Shen Y, Wang S, Shen Q, Zhou X. The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Lett. 2018;415:117\u201328.","journal-title":"Cancer Lett"},{"issue":"18","key":"3625_CR42","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-08-0377","volume":"14","author":"LY Kong","year":"2008","unstructured":"Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, et al. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res. 2008;14(18):5759\u201368.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3625_CR43","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.3390\/ijms18061234","volume":"18","author":"TT Huang","year":"2017","unstructured":"Huang TT, Su JC, Liu CY, Shiau CW, Chen KF. Alteration of SHP-1\/p-STAT3 signaling: a potential target for Anticancer Therapy. Int J Mol Sci. 2017;18(6):1234.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3625_CR44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.canlet.2015.11.039","volume":"371","author":"TI Chao","year":"2016","unstructured":"Chao TI, Tai WT, Hung MH, Tsai MH, Chen MH, Chang MJ, et al. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. Cancer Lett. 2016;371(2):205\u201313.","journal-title":"Cancer Lett"},{"issue":"11","key":"3625_CR45","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1158\/0008-5472.CAN-07-6696","volume":"68","author":"KS Ahn","year":"2008","unstructured":"Ahn KS, Sethi G, Sung B, Goel A, Ralhan R, Aggarwal BB. Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res. 2008;68(11):4406\u201315.","journal-title":"Cancer Res"},{"issue":"1","key":"3625_CR46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1158\/1541-7786.MCR-09-0257","volume":"8","author":"SK Sandur","year":"2010","unstructured":"Sandur SK, Pandey MK, Sung B, Aggarwal BB. 5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization. Mol Cancer Res. 2010;8(1):107\u201318.","journal-title":"Mol Cancer Res"},{"issue":"8","key":"3625_CR47","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","volume":"82","author":"J Paik","year":"2022","unstructured":"Paik J. Nivolumab Plus Relatlimab: first approval. Drugs. 2022;82(8):925\u201331.","journal-title":"Drugs"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-024-03625-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-024-03625-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-024-03625-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T16:02:19Z","timestamp":1735401739000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-024-03625-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3625"],"URL":"https:\/\/doi.org\/10.1186\/s12935-024-03625-6","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"6 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Medical Ethics Committee of the Second Affiliated Hospital of Harbin Medical University (Ethical Review Approval Number: SYDW2024-074).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors gave their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"435"}}